期刊文献+

剂量密集化疗在HER-2过表达乳腺癌辅助化疗中的应用

下载PDF
导出
摘要 目的:探讨HER-2过度表达的高危乳腺癌,密集疗法的毒性反应、生活质量、局部复发及生存率的相关性,寻求高危乳腺癌低成本、高疗效的个体化治疗策略。方法:对80例HER-2(++~+++)的乳腺癌患者,随机分为两组,化疗方案为紫杉醇联合表阿霉素,密集疗法组采用2周方案,常规化疗组采用3周方案。均进行6个周期,评价毒性反应和生活质量,观察局部复发和生存率。结果:血液学毒性,按WHO制定的统一标准分为0、Ⅰ、Ⅱ、Ⅲ、Ⅳ度,经统计学处理,差异无显著性;生活质量在生理功能、生理职能、总体健康、情感职能、精神健康方面两组间有差异,在躯体疼痛、活力、社会功能方面两组间无差异;生存率方面1年、2年、3年生存期和总生存期无差异。局部复发比较,两组间有差异。结论:初步研究结果提示,剂量密集疗法初显成效,有望成为HER-2(+)高危乳腺癌群体个体化治疗的优化策略。
出处 《中国社区医师(医学专业)》 2010年第16期52-53,共2页
  • 相关文献

参考文献7

二级参考文献14

  • 1赵卫红,徐兵河,李青.密集化疗在恶性肿瘤治疗中的应用[J].中华医学杂志,2006,86(5):357-359. 被引量:5
  • 2Paridaens R, Biganzoli L, Bnming P, et al. Paclitaxel versus Doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer:a European organization for research and treatment of cancer randomized study with cruss-over. J Clin Oncol, 2000, 18:724-733.
  • 3Henderson C, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer. J Clin Oncol, 2003, 21:976-983.
  • 4Memorial Sloan-Kettering Cancer Center. The use of taxanes in early breast cancer. EJC Supplements, 2003, 1:1-10.
  • 5Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep, 1977, 61:1307-1317.
  • 6Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol, 1997, 24(4 suppl 10) :3-10.
  • 7Altundag K, Altundag O, Elkiran ET, et at. Addition of granulocyteconoly stimulating factor (G-CSF) to adjuvant treatment may increase survival in patients with operable breast cancer: interaction of G-CSF with dormant micrometastatic breast cancer cells. Med Hypotheses, 2004, 63:56-58.
  • 8Epstein RJ. The CXCL12-CXCR4 ehemotaetie pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer, 2004, 4: 901-909.
  • 9Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol, 2003,21:1431-1439.
  • 10Kummel S, Krocker J, Kohls A, et al. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for nodepositive breast cancer. BJC, 2006, 94 : 1237-1244.

共引文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部